Your browser doesn't support javascript.
loading
Cost-effectiveness of surveillance intervals after curative resection of colorectal cancer.
Takayama, Yuji; Tsukamoto, Shunsuke; Kudose, Yozo; Takamizawa, Yasuyuki; Moritani, Konosuke; Esaki, Minoru; Kanemitsu, Yukihide; Igarashi, Ataru.
Afiliação
  • Takayama Y; Department of Colorectal Surgery, National Cancer Center, Tokyo, Japan.
  • Tsukamoto S; Department of Colorectal Surgery, National Cancer Center, Tokyo, Japan.
  • Kudose Y; Department of Colorectal Surgery, National Cancer Center, Tokyo, Japan.
  • Takamizawa Y; Department of Colorectal Surgery, National Cancer Center, Tokyo, Japan.
  • Moritani K; Department of Colorectal Surgery, National Cancer Center, Tokyo, Japan.
  • Esaki M; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center, Tokyo, Japan.
  • Kanemitsu Y; Department of Colorectal Surgery, National Cancer Center, Tokyo, Japan.
  • Igarashi A; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Jpn J Clin Oncol ; 54(6): 637-646, 2024 Jun 01.
Article em En | MEDLINE | ID: mdl-38376792
ABSTRACT

BACKGROUND:

Major guidelines consistently recommend 5 years of postoperative surveillance for patients with colorectal cancer. However, they differ in their recommendations for examination intervals and whether they should vary according to disease stage. Furthermore, there are no reports on the cost-effectiveness of the different surveillance schedules. The objective of this study is to identify the most cost-effective surveillance intervals after curative resection of colorectal cancer.

METHODS:

A total of 3701 patients who underwent curative surgery for colorectal cancer at the National Cancer Center Hospital were included. A cost-effectiveness analysis was conducted for the five surveillance strategies with reference to the guidelines. Expected medical costs and quality-adjusted life years after colorectal cancer resection were calculated using a state-transition model by Monte Carlo simulation. The incremental cost-effectiveness ratio per quality-adjusted life years gained was calculated for each strategy, with a maximum acceptable value of 43 500-52 200 USD (5-6 million JPY).

RESULTS:

Stages I, II and III included 1316, 1082 and 1303 patients, respectively, with 45, 140 and 338 relapsed cases. For patients with stage I disease, strategy 4 (incremental cost-effectiveness ratio $26 555/quality-adjusted life year) was considered to be the most cost-effective, while strategies 3 ($83 071/quality-adjusted life year) and 2 ($289 642/quality-adjusted life year) exceeded the threshold value. In stages II and III, the incremental cost-effectiveness ratio for strategy 3 was the most cost-effective option, with an incremental cost-effectiveness ratio of $18 358-22 230/quality-adjusted life year.

CONCLUSIONS:

In stage I, the cost-effectiveness of intensive surveillance is very poor and strategy 4 is the most cost-effective. Strategy 3 is the most cost-effective in stages II and III.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Análise Custo-Benefício / Anos de Vida Ajustados por Qualidade de Vida Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Jpn J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Análise Custo-Benefício / Anos de Vida Ajustados por Qualidade de Vida Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Jpn J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão